CA
NZ
UK
AU
IND
US
Viatris (NASDAQ:VTRS) announced on February 25, 2026 that the FDA accepted its supplemental new drug application for MR-141, phentolamine ophthalmic solution 0.75%, as a treatment for presbyopia, the age-related loss of near focusing. A supplemental application asks the agency to broaden an existing approval. …
Opus Genetics reported second quarter 2026 results on August 6, 2026. Cash and equivalents were USD 88.8 million, up from USD 45.1 million at December 31, 2025. License and collaborationRevenuefell to USD 0.8 million from USD 2.9 million, mostly reimbursement of research services under …
On September 25, 2026 Daiichi Sankyo and Merck (NYSE:MRK) announced they had voluntarily withdrawn theBiologicslicense application for ifinatamab deruxtecan, known as I-DXd, in extensive-stage small cell lung cancer after the disease worsened on or after platinum chemotherapy. The submission sought accelerated approval. A calendar …
Core growth of 8.1 percent included about 3 percent from distributor inventory adjustments in the prior-year quarter and the timing of customer orders, so underlying growth is nearer 5 percent, simple arithmetic. Gross margin was 47.4 percent versus 45.4 percent, while adjusted gross margin …
Biohaven (NYSE:BHVN) licensed its MoDE pan-IgG degrader portfolio, BHV-1300, BHV-1310 and BHV-1320, to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries on October 8, 2026. It receives USD 80 million at signing, a USD 20 million milestone expected within about a year …
Merck (NYSE:MRK) and Daiichi Sankyo's decision to voluntarily withdraw the Biologics License Application for ifinatamab deruxtecan eliminates what several PDUFA calendar listings had flagged as a possible October 10 FDA decision date. A voluntary withdrawal differs meaningfully from an FDA rejection: it typically reflects …
According to In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx, it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. According to The company, safety was consistent …
Biohaven's license of BHV-1300 to Ono Pharma covering Japan, South Korea, Taiwan and ASEAN markets provides 80 million dollars in upfront cash plus a 20 million dollar near-term milestone, non-dilutiveCapitalthat extends the company's cash runway without requiring anEquityraise. Biohaven (NYSE:BHVN) retains rights to BHV-1300 …
According to In a release at 5:31 p.m. ET on October 7, 2026, Medtronic (NYSE:MDT), the final exchange ratio is 4.5939 MiniMed shares for each Medtronic ordinary share accepted. The offer expires at the end of October 9, 2026, at 12:00 midnight New York …
Neogen (NASDAQ:NEOG) released first quarter fiscal 2027 results for the quarter ended August 31, 2026 on October 6, 2026. Revenue of USD 222.8 million rose 6.5%, or 8.1% on a core basis. Domestic revenue was USD 110.1 million and international revenue was USD 112.7 …
Please wait processing your request...